Medical devices and digital technologies

HyAGlauc: combatting inflammation and fibrosis in post-surgery glaucoma patients

HyAGlauc is a biodegradable implant which acts to reduce post-surgical scar tissue formation following glaucoma drainage surgeries. HyAGlauc provides a mechanical support and can be loaded to deliver anti-inflammatory and anti-fibrotic molecules in a controlled manner. This biodegradable drug-delivery device inhibits inflammation and fibrosis at key stages of the wound healing process, thereby eliminating patient-administered drugs and repeat surgical procedures.

This technology is being commercialised by RCSI spin-out company LEP Biomedical.